| Glassia (alpha1-proteinase inhibitor (Human)) / Takeda |
NCT02005848: Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes |
|
|
| Completed | 2 | 70 | RoW | Alpha-1 Antitrypsin, Humman Alpha-1 Antitrypsin, Alpha-1 Proteinase Inhibitor, API, AAT, Placebo | Kamada, Ltd. | New Onset Type-1 Diabetes | 02/17 | 02/17 | | |
NCT02614872: Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation |
|
|
| Completed | 2 | 30 | RoW | GLASSIA® and Institution standard of care (SOC), GLASSIA and Institution standard of care (SOC) | Kamada, Ltd. | Transplantation, Lung Rejection | 04/19 | 05/19 | | |
|
|
NCT03385395: Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency |
|
|
| Withdrawn | 2 | 0 | NA | OctaAlpha1, Glassia | Octapharma | Alpha 1-Antitrypsin Deficiency | 12/19 | 12/19 | | |
NCT02464878: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant |
|
|
| Completed | 2 | 2 | US | Alpha 1-Antitrypsin, Glassia, Islet Transplantation, Thymoglobulin, Antithymocyte Globulin, Basiliximab, Etanercept, Enbrel | Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Iowa | Kidney Transplant, Type 1 Diabetes | 11/22 | 12/22 | | |
NCT01304537: Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus |
|
|
| Completed | 1/2 | 24 | RoW | Alpha-1 Antitrypsin 40mg (AAT, Glassia®), Alpha-1 Antitrypsin 60mg (AAT, Glassia®), Alpha-1 Antitrypsin 80mg (AAT, Glassia®) | Kamada, Ltd. | Type 1 Diabetes Mellitus | 11/12 | 11/12 | | |
NCT01523821: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) |
|
|
| Completed | 1/2 | 20 | US | Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia] | Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI) | Graft-Versus-Host Disease (GVHD) Acute on Chronic | 01/17 | 01/17 | | |
